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INTRODUCTION
Leukocyte infiltration from a blood compartment
into inflammatory sites is one of the characteristic
elements of the inflammatory process. Locally pro-
duced chemotactic agents were suggested to play
a crucial role in the leukocyte accumulation. Several
members of a newly described family of chemotactic
cytokines called chemokine are now believed to have
an important role in inducing the migration of leu-
kocytes (1-3). On the other hand, some proteases
have been recently reported to induce chemotactic
migration of leukocytes (summarized in Table 1).
Originally, thrombin, a trypsin-like serine protease
involved in blood clotting generated during vascu-
lar injury, was shown to have chemotactic activity
for monocytes and neutrophils (4, 5). Recent studies
have reported that various serine proteases can in-
duce leukocyte chemotaxis. For example, CAP37/
azurocidin was reported to have chemotactic activ-
ity for monocytes (6) and lymphocytes (7).We showed
that cathepsin G, chymase and endothelin induce
chemotactic migration of neutrophils and monocytes
(8-10). In addition to serine proteases, we recently
demonstrated that aminopeptidase N can induce
chemotactic migration of T lymphocytes (11). This
article describes recent studies on protease-induced
leukocyte chemotaxis and activation, and their role
in inflammatory and immunological disorders.
NEUTROPHIL CATHEPSIN G
Human cathepsin G is an antimicrobial chymotrypsin-like
enzyme that is found in the azurophil granules of
human neutrophils, monocytes and spleen cells
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(12) and comprises 18% of the azurophil granule
protein (13). Cathepsin G exerts a broad-spectrum
of antibacterial action in vitro against Gram-negative
and positive bacteria independent of its serine
protease activity. In addition to the antimicrobial activity,
cathepsin G can induce degradation of extracellular
matrix, vasoregulation, activation of neutrophil elastase,
and cytokine processing (13).
Chemotactic activity
Recently, Chertov et al. showed that cathepsin
G has the chemotactic activity for monocytes and
neutrophils (8). The chemotactic effect appears in
a dose-dependent manner with an optimal concen-
tration of 0.5-1 µg/ml. The monocyte chemotactic
activity of cathepsin G is more potent than thrombin.
Subcutaneous sites of cathepsin G injection in mice
were infiltrated by these inflammatory cell types
(8). The enzymatic activity of cathepsin G is required
for its in vitro and in vivo chemotactic activity because
inactivation of cathepsin G-enzymatic activity by
inhibitors for serine proteases abolished the chemotactic
activity.
T cell activation
We recently found that cathepsin G significantly
stimulated antigen-specific Ig antibody production
in association with activation of, and cytokine produc-
tion by, murine T cells (14). The injection of cathepsin
G into mice increased serum antigen-specific IgG1 and
IgG2a subclasses in vivo (Fig. 1). In vitro restimulation
of lymph node cells from immunized mice with anti-
gen showed that cathepsinG increased antigen-specific
lymphoproliferative responses and induced a marked
increase in interferon (IFN)-γ production (Table 2).
IFN-γ is responsible for the cathepsin G-enhanced
antigen-specific IgG2a response of the immunized
mice because IFN-γ, a Th-1 cytokine, is known to
be associated with cell-mediated immunity and the
preferential induction of IgG2a (15, 16). Cathepsin
G also increased antigen-specific production of the
Th2 cytokine, interleukin (IL)-4 (Table 2). This may
account for the antigen-specific IgG1 production be-
cause IL-4 is known to be critical for the expansion
of Th2 responses characterized by increased synthe-
sis of IgG1 (17). These results suggest that neutrophil
cathepsin G may have a role in the regulation of
lymphocyte-dependent immunological reactions. Pre-
vious studies reported that human cathepsin G se-
lectively stimulates both human T and B lymphocytes
(18) and increases IFN-γ production by T cells (14).
The mitogenic activity of cathepsin G was dependent
on its enzymatic activity since pretreatment with
diisopropylfluorophosphate (DFP) ablated the en-
hancement of proliferation. These results suggest
that enzymatically active cathepsin G up-regulates
antigen-specific Ig antibody production, and may act
as an immune adjuvant in addition to possessing anti-
bacterial action. Although Yamazaki andAoki showed
that cathepsin G exhibits specific binding to human
lymphocytes (19), the receptor for cathepsin G has
not been determined.
CAP37/AZUROCIDIN
Cathionic antimicrobial protein (CAP) ofMW37 kD,
also termed azurocidin, was first isolated and purified
from the granules of human neutrophils by Shafer
et al. in 1984 (20). CAP37/azurocidin is a serine
Table 1. Proteases with chemotactic activity for leukocytes
Preteases Cell source (s) Target cells
Thrombin
CAP37/azurocidin
Cathepsin G
Endothelin
Chymase
Aminopeptidase N
Neutrophils
Neutrophils
Monocytes
Mast cells
Neutrophils
Endothelial cells
Mast cells
Monocytes
Macrophages
Fibroblasts
Monocytes
Neutrophils
Monocytes
Lymphocytes
Monocytes
Neutrophils
Monocytes
Neutrophils
Monocytes
Neutrophils
Lymphocytes (CD4+>CD8+)
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protease homolog exhibiting 45% sequence indentity
to neutrophil elastase, and 30-37% identity to several
other granule serine proteases (21).
Chemotactic activity
CAP37/azurocidin was shown to be a potent
chemoattractant for monocytes in 1990 (6). This
monocyte chemotactic activity is 80-100% that of
N-formyl-methionyl-leucyl-phenylalanine (fMLP).
Later, Flodgaard et al. demonsterated that CAP39/
azurocidin has chemotactic activity for fibroblasts
(22). The bactericidal activity of CAP37/azurocidin
occurs at acidic pH whereas its chemotactic activity
occurs at neutral pH. Moreover, the concentration
of CAP37/azurocidin required for chemotaxis is sig-
nificantly less than that required for antibacterial
activity. Recently, Chertov et al. showed that CAP37/
azurocidin induced chemotactic migration of T
lymphocytes in vitro and in vivo (7). CAP37/azurocidin
represents the T cell chemotactic activity at nanomolar
concentrations though it carries out the antimicrobial
activity at micromolar concentrations.
Fig. 1 IgG1 and IgG2 levels of serum keyhole limpet hemocyanin (KLH)-specific antibodies were increased by administration of
human cathepsin G. Mice were immunized s.c. with 50 µg of KLH on Day 1, and treated s.c. with 5-500 ng cathepsin G, 500 ng boiled
cathepsin G, or PBS alone daily from Day 1 to 5. On Day 10 KLH-specific antibodies in sera were assayed by ELISA. Values show
means and SD of measurements from three mice. ＊indicates statistically significant differences (p<0.05) relative to mice treated
with KLH alone.
Table 2. Effect of cathepsin G on KLH-induced cytokine release by lymph node cells from immunized micea
in vivo treatment IFN-γ (pg/ml) IL-4 (pg/ml)
KLH + PBS
KLH + cathepsin G (5 ng)
KLH + cathepsin G (50 ng)
KLH + cathepsin G (500 ng)
KLH + boiled cathepsin G
47.0 (21.6)
159.3 (38.7)b
224.3 (22.4)c
289.3 (42.7)c
32.7 (9.8)
231.3 (33.1)
500.7 (61.5)c
860.0 (146.1)c
651.0 (126.6)c
285.7 (26.1)
a Mice were immunized s.c. with 50 µg KLH along with various doses of cathepsin G, 500 ng of boiled cathepsin G or
PBS alone. After 10 days, single cells prepared from draining lymph nodes were incubated with 50 µg/ml of KLH in
vitro. After 48h, culture supernatants were harvested, and assayed for IFN-γ and IL-4 levels by ELISA. Values means
(SD) from three mice.
b Significantly different from the values of mice treated with KLH alone (p<0.05)
c Significantly different from the values of mice treated with KLH alone (p<0.01)
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CHYMASE
Chymase is a major chymotrypsin-like serine protease
expressed in the secretory granules of mast cells in
many mammalian species (23). It was recently clarified
that chymase was involved in the inflammatory pro-
cesses of a variety of diseases. Chymase degrades
constituents of extracellular matrix by the activation
of matrix metalloprotease (MMP)-1 and MMP-3 (24),
suggesting that this enzyme participates in the
pathogenesis of matrix degradation in the rheuma-
toid joint, at sites of tumor invasion, and in human
atherosclerotic lesions. Mizutani et al. showed that
human chymase can convert an inactive precursor
31 kD IL-1 β to a biologically active IL-1 β (25). On
the other hand, chymase stimulates secretion from
cultured airway submucosal gland serous cells (26).
Chemotactic activity
Human chymase was recently shown to have the
potent chemotactic activity for monocytes and
neutrophils in concentration ranging from 0.1 to
10 µg/ml as well as human cathepsin G (Fig. 2A
and 2 B). The activity was as potent as that of fMLP.
The proteolytic activity of chymase participates in
the chemotactic activity. Although mast cells have
been reported to produce chemokines, such as
macrophage inflammatory protein (MIP)-1α, MIP-1β
and monocyte chmoattractant protein (MCP)-1 (27),
which may induce leukocyte migration into the
inflammatory lesions, mast cell chymase may be one
of the candidates for mast cell-derived chemoattractants
for inflammatory cells. A recent report demonstrated
that the injection of chymase into mice induced the
accumulation of neutrophils and eosinophils at the
injection site (28). Findings about chymase-induced
chemotaxis indicate that chymase can directly induce
chemotaxis of leukocytes into the region.
ENDOTHELIN
Endothelin (ET) was first isolated from culture
medium of porcine endothelial cells and shown to be
a vasoconstrictor (29). ET-1 (1-31) is a novel 31-amino
acid length peptide derived from big ET-1 by chymase
or other chymotrypsin-type proteases, and is a pre-
dominant ET peptide in human neutrophils (30).
Cathepsin G can transiently convert big ET-1 to ET-1
(1-31) and can degrade ET-1 (1-31).
Chemotactic activity
Recently, ET-1 (1-31) was reported to exhibit chemotactic
activity toward neutrophils and monocytes (10). The
functions of ET are known to be mediated by two
distinct subtypes of receptors, ETA and ETB recep-
tors. The chemotactic effect of ET-1 (1-31) may be
mediated by ETA receptor because the chemotactic
effects and an increase in intracellular free Ca2+
caused by ET-1 (1-31) were inhibited by the ETA re-
ceptor antagonist but not by the ETB receptor an-
tagonist. ET-1 (1-21) was also reported to have the
chemotactic effect (31) but the chemotactic effect
of ET-1 (1-31) was considerably greater than that
of ET-1 (1-21).
AMINOPEPTIDASE N
Aminopeptidase N is a membrane-bound metalloprotease,
and was shown to be identical to CD13 (32), a 150-kD
cell surface glycoprotein, which was originally used
as a marker for subpopulations of hematopoietic cells
(33). CD13/aminopeptidase N is widely distributed
in a variety of mammalian cells such as monocytes/
macrophages, fibroblasts, neutrophils, endothelial
cells and epithelial cells (34, 35). This peptidase was
shown to be involved in the degradation of extracellular
matrix in tumor invasions (36) and the processing
of peptide for presentation by antigen-presenting cells
(37). Although little information is available concern-
ing the regulation of CD13/aminopeptidase N expres-
sion in human diseases, recent studies have reported
that lymphokines such as IFN-γ and IL-4 up-regulate
the expression of CD13/aminopeptidase N in all cell
types (34, 38).
Chemotactic activity for T lymphocytes
We recently reported that CD13/aminopeptidase
N induces chemotactic migration of human lympho-
cytes (11) (Fig. 3). Chemotactic activity induced by
CD13/aminopeptidase N is equivalent to that of 50
ng/ml of MIP-β. The enzymatic activity of CD13/
aminopeptidase N is necessary in its chemotactic
activity because treatment with bestatin, a specific
inhibitor for aminopeptidases, reduces the chemotactic
activity for lymphocytes. CD13/aminopeptidase N
also manifested chemotactic activity for purified hu-
man CD4+ and CD8+ T lymphocytes, but the response
of CD4+ T cells was greater than that of CD8+ T
cells. Since CD13/aminopeptidase N does not induce
chemotaxis of monocytes or neutrophils, CD13/
aminopeptidase N shows chemotactic activity spe-
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Fig. 2. A) Monocyte migration induced by chymase and
cathepsin G. Monocytes were separated from the pe-
ripheral blood of healthy donors by centrifugal elutriation
in a Beckman JE-5.0 elutriation system. The results are
expressed as the number of migrated cells in 1 HPF.
Fifty ng/ml of MCP-1 and 10-8 M of fMLP were used as
positive controls for monocyte chemotaxis. ＊ and † in-
dicate significance of differences for comparing the
value of medium control (p<0.05) and for comparing
the value of cathepsin G (p<0.01), respectively.
A
Fig. 2. B) Neutrophil migration induced by chymase and
cathepsin G. Neutrophils were purified from the periph-
eral blood of healthy donors by the sedimentation meth-
od. The results are expressed as the number of migrated
cells in 1 HPF. Fifty ng/ml of IL-8 and 10-8 M of fMLP
were used as positive controls for neutrophil chemotaxis.
＊ and † indicate significance of differences for comparing
the value of medium control (p<0.05) and for comparing
the value of cathepsin G (p<0.05), respectively.
B
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cific for lymphocytes.
CLINICAL SIGNIFICANCE
Neutrophil-derived serine proteases
Infiltrations of monocytes and lymphocytes into
inflamed lesions are normally preceded by an initial
influx of neutrophils. Neutrophil-cathepsin G may
have a role in the development of further accumu-
lation of neutrophils and monocytes into inflamma-
tory sites by its chemotactic activity. Antibiotic proteases
such as cathepsin G and CAP37/azurocidin secreted
by neutrophils play a major role in resistance to the
early stages of infections by killing microbes (13,
39). Following phagocytosis of microbial agents or
other particulate substances, these proteases are re-
leased from the granules into phagocytic vacuoles
and also into the extracellular milieu (40). Kudo et al.
showed that depleting rat neutrophils by treatment
with anti-rat neutrophil antiserum reduced subsequent
development of chronic delayed-type hypersensitiv-
ity reactions (41, 42). Similarly, it has also been re-
ported that suppression of neutrophil migration to
inflammatory sites by infusion of anti-IL-8 mAb de-
creased not only acute inflammatory responses (43)
but also delayed-type hypersensitivity responses (44).
Recently, it was demonstrated that IL-8, a chemokine
with potent chemotactic and activating effects on hu-
man neutrophils, induced neutrophil accumulation at
the injection site followed by T cell infiltration in SCID
mice administered human T cells (45). These results
suggest that neutrophils could release chemoattractants
that mediate T cell accumulation at sites of inflam-
mation. We also showed that cathepsin G up-regulates
antigen-specific Ig production as a result of T cell
activation (14). Taken together, neutrophil cathepsin
G and CAP37/azurocidin may play a role in the com-
munication between cell types involved in innate
or natural resistance mediated, for example, by
neutrophils and those responsible for adaptive immunity
such as T and B cells.
Mast cell chymase
When mast cells are stimulated by inflammatory
mediators, mast cells increase in number in the le-
sion and release a variety of chemical mediators and
proteases into the extracellular environment (46).
The role of mast cells in immediate-type reactions of
allergic diseases has been extensively studied, but
the role in delayed-type reactions has not been under-
stood. Although the late phase reactions in allergic
disorders such as bronchial asthma are associated
with enhanced leukocyte infiltration at sites of aller-
gen challenge, the striking recruitment of leukocytes
are incompletely understood in mechanical terms.
Findings about chymase-induced leukocyte chemotaxis
suggest that chymase released from mast cells in
immediate-type reactions may play a role in the ac-
Fig. 3. Chemotactic and enzymatic activities of CD13/
aminopeptidase N for human lymphocytes. Lympho-
cytes were separated from the peripheral blood of
healthy donors by centrifugal elutriation in a Beckman
JE-5.0 elutriation system. MIP-1β is included as a
positive control. The results are expressed as the
chemotaxis index (CI) which represents the ratio of
the number of cells in HPF in the test to control sam-
ples (medium control). Columns show the enzymatic
activity of CD13/aminopeptidase N which was assayed
fluorometrically with L-leucine-AMC as a substrate and
was expressed in nanomoles of substrate cleaved per
hour. Results are expressed as means±SEM. ＊ in-
dicates significantly different from the value of me-
dium control (p<0.05).
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cumulation of inflammatory cells in the development
of subsequent late-phase reactions and the chronic
inflammatory responses of allergic diseases as a
chemoattractant.
Mast cells play a major role not only in allergic
diseases but also in a number of non-allergic immune
reactions, such as fibrotic process, host responses
to neoplasms, angiogenesis and tissue remodeling.
In the lung, mast cell hyperplasia has been demon-
strated in patients with fibrotic lung diseases (47,
48) and in a number of experimental models of pul-
monary fibrosis, including exposure to asbestos,
silica, and bleomycin (49-51). Since the involvement
of monocytes and neutrophils have a provoked role
in the pathogenesis of fibrotic lung diseases, leuko-
cyte chemotaxis induced by mast cell chymase
evokes leukocyte migration into the disease sites in
these disorders. Mast cell chymase may be one of
the initial triggers of infiltration of neutrophils and
monocytes and may play a role in the inflammatory
process in various diseases.
CD13/aminopeptidase N
CD13/aminopeptidase N was reported to have a
significant role in the pathogenesis of pulmonary
sarcoidosis as a T cell chemoattractant(11).High
activity of CD13/aminopeptidase N and lymphocyte
chemotactic activity is present in the bronchoalveolar
lavage fluid (BALF) from patients with sarcoidosis.
The chemotactic activity for lymphocytes is partial-
ly decreased by the treatment of the BALF with
bestatin, a specific inhibitor for aminopeptidases.
Sarcoidosis is a chronic inflammatory disease in which
there is a systemic granulomatous process and the
lungs are most commonly involved in this disorder.
Lung parenchymal lesions in patients with sarcoidosis
are characterized by alveolitis associated with the
infiltration of CD4+ T lymphocytes and noncaseating
granuloma formation (52). Although the triggering
agent of sarcoidosis is uncertain, lymphokines re-
leased by activated CD4+ T lymphocytes play a piv-
otal role in the inflammatory process of this disorder.
Accordingly, CD13/aminopeptidase N may have a
role in T lymphocyte involvement in the sarcoid lung.
Recently, we reported that CD13/aminopeptidase
N has a significant role in the pathogenesis of joint
inflammation in rheumatoid arthritis (manuscript
submitted).
CONCLUSION
The migration of neutrophils, mast cells, monocytes
and lymphocytes into inflamed lesions is one of the
fundamental events of inflammation. During the acute
phase of inflammatory and allergic diseases, the pre-
dominant migrated cells are neutrophils and mast
cells, respectively. Subsequently, during the subacute
and chronic phases, monocytes and lymphocytes
are mainly migrated. Thus, the chemotactic activity
for monocytes and lymphocytes of neutrophil-derived
serine proteases and mast cell-derived chymase
may have a critical role in chronic inflammation
and delayed-type hypersensitivity. A greater under-
standing of the regulation of the production and
action of this enzyme may lead to new insights for
the control and treatment of inflammation in aller-
gic and nonallergic diseases.
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